gliclazide / Generic mfg. - LARVOL DELTA

Synthesis and antidiabetic evaluation of novel Tetrahydroacridine derivatives with computational insights. (PubMed, Sci Rep) - "The synthesized tetrahydroacridine (THA) derivatives were initially screened for antidiabetic potential through a glucose diffusion assay, where compound 4b (100 mg/kg) exhibited the highest inhibition rate (34.00%) at the lowest concentration tested, outperforming the reference drug Gliclazide...These integrated findings highlight the potential of tetrahydroacridine derivatives as promising scaffolds for the development of new antidiabetic candidates with multitarget activity, favorable drug-like properties and minimal toxicity risk. Further in-depth SAR, enzyme inhibition, and pharmacodynamic studies are warranted to advance these candidates toward clinical relevance."

Journal

Gliclazide Challenge Testing as an Alternative Diagnostic Tool for Hepatocyte Nuclear Factor-1-Alpha Maturity Onset Diabetes of the Young. (PubMed, Eur J Case Rep Intern Med) - "Young patients with atypical diabetes (negative autoantibodies, preserved C-peptide, recurrent hypoglycaemia on insulin) should prompt consideration of monogenic diabetes, and the Exeter maturity-onset diabetes of the young calculator is a valuable screening tool for clinicians.A gliclazide challenge test with serial C-peptide measurement can provide a simple, functional assessment of sulfonylurea sensitivity, supporting the diagnosis of maturity-onset diabetes of the young, in centres where genetic testing is limited or delayed.Early recognition of maturity-onset diabetes of the young allows safe transition from insulin to sulfonylureas, preventing years of unnecessary injections, reducing hypoglycaemic episodes, and improving long-term quality of life."

Journal • Diabetes • Hypoglycemia • Metabolic Disorders • Type 1 Diabetes Mellitus • Type 2 Diabetes Mellitus • HNF1A

Gliclazide in type 2 diabetes: Cost-effective and clinically relevant in resource-limited settings. (PubMed, Diabetes Metab Syndr) - No abstract available

HEOR • Journal • Diabetes • Metabolic Disorders • Type 2 Diabetes Mellitus

Exploring the Evidence for Personalized Pharmacotherapy in Type 2 Diabetes-A Systematic Review. (PubMed, J Pers Med) - " We systematically searched PubMed, Scopus, and Web of Science for studies published from the earliest available records to 18 August 2025 using the following Boolean search terms: "miRNA AND gliclazide", "miRNA AND glibenclamide", "miRNA AND gliquidone", "miRNA AND glimepiride", "mirRNA AND metformin", "miRNA AND pioglitazone", "miRNA AND rosiglitazone", "miRNA AND sitagliptin", "miRNA AND vildagliptin", "miRNA AND alogliptin", "miRNA and saxagliptin", "miRNA AND linagliptin", "miRNA AND liraglutide", "miRNA and dulaglutide", "miRNA AND semaglutide", "miRNA AND tirzepatide", "miRNA AND lixisenatide", "miRNA AND empagliflozin", "miRNA AND dapagliflozin", miRNA AND insulin glargine", "miRNA AND insulin detemir", "miRNA AND insulin degludec", "miRNA AND..."

Journal • Review • Diabetes • Metabolic Disorders • Type 2 Diabetes Mellitus

Renal Functional Reserve Predicts GFR Response to Empagliflozin but Not Linagliptin or Sulfonylureas in Patients with Type 2 Diabetes (KIDNEY WEEK 2025) - "Patients received EMPA (10mg; N=20), LINA (5mg; N=27) or SU (glimepiride 1mg or gliclazide 30mg; N=24), added to stable metformin. Conclusion Postprandial RFR links to the acute GFR dip with EMPA, but not GFR changes in response to LINA or SU. As initial GFR-dipping is associated with long-term kidney benefit, RFR may be a potential biomarker to personalize SGLT2i-therapy."

Clinical • Diabetes • Metabolic Disorders • Type 2 Diabetes Mellitus

ADD2Dia: Real-World Clinical Effectiveness of Adding a Sodium-Glucose Cotransporter 2 Inhibitor to Gliclazide-Based Therapy in Type 2 Diabetes. (PubMed, Adv Ther) - P | "The first real-world study of the long-term combination of gliclazide MR and SGLT2i demonstrated its value as an effective and well-tolerated strategy in T2D management, particularly in high-risk populations. This combination provided clinically meaningful and sustained HbA1c reductions and improved cardiometabolic parameters in a diverse T2D population, with very few adverse events. These results align with current guidelines emphasizing the importance of early combination treatment and multifactorial risk management in T2D and highlight the need to address late treatment intensification indicative of clinical inertia."

Journal • Real-world evidence • Atherosclerosis • Cardiovascular • Diabetes • Infectious Disease • Metabolic Disorders • Nephrology • Obesity • Type 2 Diabetes Mellitus

Cost-Consequences of Adding Gliclazide Modified Release to Metformin in Patients with Uncontrolled Type 2 Diabetes in the United Arab Emirates. (PubMed, Adv Ther) - "Initiating gliclazide MR as an add-on treatment to metformin could help to reduce the clinical and economic burden of poorly controlled T2D among patients in the UAE. Switching patients from sitagliptin to gliclazide MR as a second-line treatment option could generate substantial cost savings."

Journal • Cardiovascular • Congestive Heart Failure • Diabetes • Heart Failure • Metabolic Disorders • Myocardial Infarction • Type 2 Diabetes Mellitus

Prevalence and Predictors of Post-coital Hypoglycemia in Diabetes Mellitus. (PubMed, Cureus) - "The use of certain oral diabetic medications, including metformin, sitagliptin, and gliclazide-sulfonylurea, was also associated with higher rates of post-coital hypoglycemia...Healthcare providers should incorporate discussions about sexual health and hypoglycemia risk into routine diabetes care, particularly for high-risk groups such as insulin users and T1DM patients. Future research should focus on developing effective strategies to prevent and manage post-coital hypoglycemia, thereby improving the quality of life for individuals with diabetes."

Journal • Diabetes • Hypoglycemia • Metabolic Disorders • Type 1 Diabetes Mellitus • Type 2 Diabetes Mellitus

Synergism of Synthetic Sulfonamides and Natural Antioxidants for the Management of Diabetes Mellitus Associated with Oxidative Stress. (PubMed, Curr Issues Mol Biol) - "Promising results have been achieved through dual therapies that combine antioxidants (such as sesame oil, naringin, alpha-lipoic acid, resveratrol, and quercetin) with sulfonylureas (including glipizide, glibenclamide, gliclazide, and glimepiride). These recent advancements in synthetic sulfonamide research point to a promising future in diabetes management, especially considering the dual functionalities demonstrated by in vivo studies-specifically, their antidiabetic and antioxidant effects. Moreover, the synergy between sulfonamides and other antioxidant agents represents a beneficial strategy for optimizing future chemical structures, potentially allowing for their integration into personalized treatments aimed at combating T2DM."

Journal • Review • Diabetes • Metabolic Disorders • Type 2 Diabetes Mellitus

Comparative cardiovascular risk of sulfonylureas with low- and high-affinities for cardiac mitochondrial adenosine triphosphate-sensitive potassium channels versus dipeptidyl peptidase-4 inhibitors in patients with type 2 diabetes: A cohort study. (PubMed, Diabetes Obes Metab) - "Initiating low-affinity mitoKATP-channel sulfonylureas demonstrated cardiovascular safety comparable to DPP-4i, whereas high-affinity sulfonylureas were linked to increased cardiovascular risk and all-cause mortality. These findings suggest low-affinity sulfonylureas are a safer alternative to high-affinity agents and as safe as DPP-4i. They may be appropriate for individuals with diabetes when newer therapies are inaccessible or unnecessary."

Journal • Cardiovascular • Diabetes • Ischemic stroke • Metabolic Disorders • Myocardial Infarction • Type 2 Diabetes Mellitus

Erythrodermic Psoriasis in a 91-Year-Old Patient: A Diagnostic Reflex Worth Retaining (EADV 2025) - "Case report: A 91-year-old female with a medical history of type 2 diabetes (on gliclazide), arterial hypertension, and cardiopathy (managed with losartan, carvedilol, and aspirin) presented with a 4-month history of a generalized scaly rash accompanied by intense pruritus...Systemic methotrexate therapy was considered but deferred due to diffuse ground-glass opacities observed on thoracic CT, requiring further pulmonary investigation... This case highlights the exceptional occurrence of de novo erythrodermic psoriasis in a 91-year-old, emphasizing the importance of medication review—particularly long-term beta-blockers like carvedilol, which showed a significant epidemiological association with psoriasis. The diagnosis was supported by classic nail, dermoscopic findings and histology, while exclusion of Sézary syndrome guided management. Discontinuation of carvedilol, cautious topical and phototherapy approaches led to improvement, underscoring the need for trigger..."

Clinical • Reflex • Cardiovascular • Cutaneous T-cell Lymphoma • Dermatology • Dermatopathology • Diabetes • Eosinophilia • Hematological Disorders • Immunology • Metabolic Disorders • Mycosis Fungoides • Pruritus • Psoriasis • Pulmonary Arterial Hypertension • Sezary Syndrome • Type 2 Diabetes Mellitus • CD4 • CD8

Green Nail Syndrome from Serratia marcescens in a 62-Year-Old Filipino Female (EADV 2025) - "Materials & We report the case of a 62-year-old female with a history of hypertension and a seven-year history of non-insulin- dependent diabetes mellitus, maintained on Gliclazide 60 mg once daily and a combination of Linagliptin and Empagliflozin after dinner...However, culture and sensitivity tests demonstrated a heavy growth of Serratia marcescens, sensitive to amikacin, cefepime, ceftazidime, ciprofloxacin, gentamicin, trimethoprim-sulfamethoxazole, ceftriaxone, ertapenem, and meropenem; but resistant to cefuroxime, amoxicillin/clavulanic acid, cefoxitin, and cefuroxime axetil... This report documents a rare case of green nail syndrome attributed to Serratia marcescens, a pathogen uncommonly associated with this condition. It highlights the importance of considering less common pathogens in the differential diagnosis of green nail syndrome, particularly in patients with underlying comorbidities such as diabetes mellitus. Accurate microbiological identification..."

Cardiovascular • Dermatology • Diabetes • Hypertension • Infectious Disease • Metabolic Disorders • Mood Disorders • Pruritus

Fixed Drug Eruption in Diabetes: The Intersection of Drug Hypersensitivity and Metabolic Disease (EADV 2025) - "Case report: A 56-year-old female patient with type 2 diabetes, treated with Diamicron for two years, presented with pruritic skin lesions accompanied by a few rapidly ruptured blisters, evolving over one day. This case illustrates a rarely reported association between fixed drug eruption and type 2 diabetes mellitus. While cotrimoxazole is a recognized cause of FDE, little is known about its behavior in diabetic patients. Diabetes may alter inflammatory responses and delay healing, potentially influencing the clinical course and sequelae of FDE."

Diabetes • Gastrointestinal Disorder • Immunology • Inflammation • Metabolic Disorders • Type 2 Diabetes Mellitus • Vasculitis

Eco-friendly microextraction technique using SFO-DLLME coupled with HPTLC for plasma analysis of metformin and imeglimin. (PubMed, J Chromatogr B Analyt Technol Biomed Life Sci) - "This study aimed to develop and validate a green, sensitive, and high-throughput analytical method for the simultaneous determination of metformin and imeglimin in plasma samples using gliclazide as an internal standard. Furthermore, the validated method was successfully applied to real samples (human plasma) to assess the concentration, thereby demonstrating the potential value of the method for routine use. This method provides a green, efficient, and validated strategy for the bioanalysis of antidiabetic drugs in human plasma, supporting its potential application in routine clinical diagnostics and therapeutic drug monitoring."

Journal

Systemic lipid and glucose modulation differentially affects cognitive function and neuroinflammation in a mouse model of Alzheimer's disease. (PubMed, Front Neurosci) - "We investigated the effects of two FDA-approved metabolic agents-Alirocumab, a PCSK9 inhibitor that lowers LDL cholesterol, and Gliclazide, a sulfonylurea that enhances insulin secretion-in male 5xFAD mice, a transgenic model of AD. These findings demonstrate that systemic modulation of lipid and glucose metabolism can influence neurodegenerative and synaptic processes in AD. The results support metabolic interventions as a potential strategy to modify AD progression through peripheral-central metabolic crosstalk."

Journal • Preclinical • Alzheimer's Disease • CNS Disorders • Cognitive Disorders • Inflammation • Metabolic Disorders • LEP • SYP

Exploring the hypoglycemic potential of fresh, semangit, and bosok tempe: A comparative metabolite profile. (PubMed, Narra J) - "Tempe and gliclazide significantly reduced blood glucose in diabetic rats in vivo, with semangit and bosok tempe restoring levels close to normal...PCA separated samples by fermentation stage, highlighting metabolite accumulation with prolonged fermentation. The findings revealed that bosok tempe from non-germinated soybeans had the highest abundance of bioactive metabolites, including isoflavones, which likely contributed to its superior antioxidant and hypoglycemic potential compared to other tempe types."

Journal • Diabetes • Metabolic Disorders

Glycaemic overtreatment and sarcopenia among older diabetic patients having multi-comorbid: a cross-sectional study (EASD 2025) - "Among glycemic overtreated patients, metformin (64.0%) was the most frequently described glucose-lowering medication (GLM), and using insulin (12.0%) and gliclazide MR (30.2%) were not significantly associated with increase odd ratio of severe hypoglycemia (2.9% and 2.1%, respectively). Glycemic overtreatment was common and related with higher odds ratio for sarcopenia and low lean mass in multimorbid diabetic older patients. Further longitudinal study is necessary to emphasize this casual relationship."

Clinical • Observational data • Diabetes • Metabolic Disorders • Severe Hypoglycemia

The Diabetes and Ramadan global survey: outcomes among people with type 2 diabetes using sulfonylureas vs non-insulin antidiabetic agents (EASD 2025) - "Numerous studies have demonstrated that second-generation sulfonylureas (SU) such as gliclazide and glimepiride are preferable to older drugs within this class...Metformin and DPP4-inhibitors were the most frequently used concomitant medications... In this global survey, T2D patients using modern SU were able to fast at the same frequency as non-SU users. Among 2nd generation SU, the gliclazide MR group had the highest rates of fasting days and the lowest rates of symptomatic hypoglycaemia."

Clinical • Diabetes • Hypoglycemia • Metabolic Disorders • Type 2 Diabetes Mellitus

Systemic lipid and glucose modulation differentially affects cognitive function and neuroinflammation in a mouse model of Alzheimer's disease (Frontiers) - "In this study, we investigated the effects of two FDA-approved metabolic agents-Alirocumab, a PCSK9 inhibitor that lowers LDL cholesterol, and Gliclazide, a sulfonylurea that enhances insulin secretion-on neuropathology, synaptic function, and cognition in male 5xFAD mice, a transgenic model of AD....Alirocumab significantly improved spatial working memory, restored hippocampal long-term potentiation, and normalized synaptophysin expression. Gliclazide reduced neuroinflammation and partially preserved glial and neuronal markers. Both treatments lowered brain amyloid burden and modulated adipokine levels, with Alirocumab elevating leptin and omentin in both brain and serum."

Preclinical • Alzheimer's Disease

Translating Basic Science to Clinical Applications: A Narrative Review of Repurposed Pharmacological Agents in Preclinical Models of Diabetic Neuropathy. (PubMed, Biomedicines) - "A wide array of repurposed drugs-including antidiabetics (metformin, empagliflozin, gliclazide, semaglutide, and pioglitazone), antihypertensives (amlodipine, telmisartan, aliskiren, and rilmenidine), lipid-lowering agents (atorvastatin and alirocumab), anticonvulsants (topiramate and retigabine), antioxidant and neuroprotective agents (melatonin), and muscarinic receptor antagonists (pirenzepine, oxybutynin, and atropine)-have shown promising results in rodent models, reducing neuropathic pain behaviors and modulating underlying disease mechanisms. By bridging basic mechanistic insights with pharmacological interventions, this review aims to support translational progress toward mechanism-based therapies for DN."

Journal • Preclinical • Review • Diabetic Neuropathy • Inflammation • Neuralgia • Pain

Lipoprotein levels and statin treatment related to dementia and cognitive decline in individuals with type 2 diabetes: an observational analysis from the ADVANCE study. (PubMed, Cardiovasc Diabetol) - "We observed an association between LDL levels, but not statin treatment, and incident dementia/CD. Although causality cannot be determined by our study, the results are in line with multiple randomised controlled trials. However, to understand the long-term effects of lipid levels and statin treatment on dementia/CD, studies of longer follow-up are still needed."

Journal • Alzheimer's Disease • Cardiovascular • CNS Disorders • Dementia • Diabetes • Mental Retardation • Metabolic Disorders • Psychiatry • Type 2 Diabetes Mellitus

Identification and mechanistic insights of ubiquitin-proteasome system and pyroptosis-related biomarkers in type 2 diabetes mellitus. (PubMed, World J Diabetes) - "This study identified four ubiquitin-pyroptosis-related biomarkers (ABCC8, RBP4, RASGRF1, and SLC34A2) in T2DM through bioinformatics analysis, providing novel insights into the diagnosis and treatment of T2DM."

Biomarker • Journal • Diabetes • Metabolic Disorders • Targeted Protein Degradation • Type 2 Diabetes Mellitus • RASGRF1 • RBP4 • SLC34A2

HbA1c Variability in Type II Diabetes (clinicaltrials.gov) - P=N/A | N=150 | Active, not recruiting | Sponsor: Weill Cornell Medical College in Qatar | Trial completion date: Oct 2024 ➔ Oct 2026

Trial completion date • Diabetes • Metabolic Disorders • Type 2 Diabetes Mellitus

Therapeutic impact of vildagliptin vs. gliclazide on insulin resistance and advanced glycated end product levels in newly diagnosed Egyptian diabetics: a randomized controlled trial. (PubMed, Eur J Clin Pharmacol) - "Vildagliptin showed a promising effect on improving type 2 diabetes mellitus-related complications by reducing advanced glycated end-product levels and insulin resistance. Additionally, vildagliptin reveals a favorable impact on weight reduction and glycated hemoglobin values."

Journal • Diabetes • Metabolic Disorders • Type 2 Diabetes Mellitus

Drug Repurposing Patent Applications October-December 2024. (PubMed, Assay Drug Dev Technol) - "Significantly, the contribution from Iceland is how to induce therapeutic hypothermia-but with entacapone, used in Parkinson's disease. The UK company, HealX, presents data showing that Angelman syndrome, an intractable neurodevelopmental disorder, could be treated with the common NSAID sulindac. Gliclazide, an old antidiabetic, could potentially treat schizophrenia, as inventors from Chinese Ping An-Shionogi report. These are only a few highlights from the stream of documents that have been issued towards the end of 2024."

Journal • CNS Disorders • Depression • Developmental Disorders • Movement Disorders • Ophthalmology • Pain • Parkinson's Disease • Psychiatry • Rare Diseases • Schizophrenia